Angelos M. Stergiou, MD is Chief Executive Officer and Vice Chairman of SELLAS Life Sciences Group. He brings more than 15 years of experience in the global pharmaceutical industry, leading companies and people from scientific research through regulatory approval to develop medicines that address compelling medical needs.
Prior to joining SELLAS, Dr. Stergiou held positions of increasing responsibility in the United States and Europe in pharma and biotechnology companies including PAION AG, Accentia Biopharmaceuticals, BioVest International, Anavex Life Sciences as well as Clinical Research Organizations. Dr. Stergiou has held specific roles ranging from Medical Director, Head of Clinical Research, Vice President and President, Product Development, with responsibility for medical affairs, clinical research and development, pharmacovigilance, clinical operations, project management, regulatory affairs, biostatistics and chemistry, manufacturing and controls (CMC) as well as Chief Medical Officer and Chief Operating Officer. He also founded a boutique NY-based health economics and pricing-reimbursement and health access company, Genesis Life Sciences, and performed work for big pharma.
Dr. Stergiou is a Fellow of the Royal Society of Medicine (UK), active member of the World Medical Association, the American Academy of Pharmaceutical Physicians and Investigators, the Association of Clinical Research Professionals, International Society for Pharmacoeconomics and Outcomes Research, amongst others Dr. Stergiou holds a Doctor of Medicine degree and is a graduate of Kentucky Wesleyan (USA) and has done elective clinical work in interventional cardiology and surgery at the General Hospital Hagen and the University of Cologne. He is a frequent speaker and lecturer at renowned Universities in the US and Europe and has experience with all major global health authorities.
William Pollett, ACA, CFA, Chief Financial Officer
William (Bill) Pollett is the Chief Financial Officer of SELLAS Life Sciences Group. Mr. Pollett brings over 25 years of financial management and capital markets experience to the Company.
Prior to joining SELLAS in September 2016, Mr. Pollett was President and Chief Executive Officer of Blue Capital, the wholly-owned asset management company of Montpelier Reinsurance Holdings Ltd (“Montpelier”; NYSE: “MRH”). In that role he raised nearly one billion dollars of capital in various private and public investment vehicles, investing primarily in catastrophe reinsurance products, including the successful Initial Public Offering in 2012 of Blue Capital Global Reinsurance Holdings Ltd on the London Stock Exchange (LSE: “BCGR”), and Blue Capital Reinsurance Holdings Ltd in 2013 on the New York Stock Exchange (NYSE: “BCRH”). Mr. Pollett concurrently served as President, Chief Executive Officer and a Director of BCRH, President, Chief Executive Officer of Blue Water Re, a licensed reinsurance company, and Blue Capital Management Ltd., a registered investment advisor, and as Chief Corporate Development and Strategy Officer and Treasurer of Montpelier. Mr. Pollett resigned from all positions at Blue Capital and Montpelier following its acquisition by Endurance Specialty Holdings Ltd. (NYSE: “ENH”) in 2015.
Prior to joining Montpelier in 2006, Mr. Pollett worked for five years with the ACE Group (now Chubb), initially as Chief Financial Officer of ACE Tempest Re, the reinsurance subsidiary and latterly as Senior Vice President and Senior Financial Analyst of ACE Limited, the holding company. Prior to the ACE Group, Mr. Pollett worked for the OIL Group of Companies for seven years in a number of roles including Controller and Treasurer and, prior to that, was an auditor with Coopers & Lybrand in London and Bermuda for five years. He holds a Bachelor of Commerce (Honours) degree from Edinburgh University, and is a Chartered Financial Analyst (CFA Institute) and Chartered Accountant (ICAEW).
Dr. Nicholas J. (Nick) Sarlis is an experienced clinician and recognized expert in the global pharmaceutical market with a focus in Oncology and Hematology. He has a deep understanding of the status of and emerging trends in clinical & translational research and patient care in Oncology at a global scale and specialized knowledge in medical affairs and late clinical development (US and EU).
As former Vice President and Head of Global Medical Affairs at Incyte Corporation, Dr. Sarlis led a global team supporting targeted and immuno-oncology pipeline agents. He led the integrated medical affairs plan to support the late clinical development of the innovative immuno-enhancer epacadostat and the original indoleamine 2,3-dioxygenase type-1 (IDO1) inhibitor. Dr. Sarlis and his team supported the highly successful successive launches of ruxolitinib [Jakafi®] – the original Janus kinase (JAK) inhibitor- in myelofibrosis and polycythemia vera. Prior to his time at Incyte, Dr. Sarlis held senior positions at Sanofi Aventis having led medical teams for launching key oncology and cancer supportive care products (US & EU).
He received his medical degree and doctorate from the University of Athens, and a Ph.D. in Molecular Biology/ Neuroendocrinology from the Imperial College in London. Sarlis is Board Certified by the American Board of Internal Medicine, and previously served as senior faculty at the National Institutes of Health and Associate Professor at MD Anderson Cancer Center.
Dr. Sarlis has published more than 130 articles (peer-reviewed papers, textbook chapters and monographs). He has received numerous awards, being most recently nominated as the recipient of the 2016 Annual Award by Cancer Research and Treatment Fund (CR&T). He is a Fellow of the American College of Physicians (FACP), the American College of Endocrinology (FACE), the Royal Society of Medicine (UK; FRSM), and the Molecular Medicine Society (FMMS).
Jonathan Eckard has over 10 years of Wall Street experience following the biotechnology sector, bringing to SELLAS both important industry insights and an understanding of the healthcare equity markets. During his time on Wall Street, he received several accolades including Institutional Investor “Best up-and-comer” and “Rising Star” in Biotechnology research.
Most recently Jonathan was a Director and Senior Equity Research Analyst at Barclays Capital Markets in New York covering the small- and mid-cap Biotechnology sector. Prior to joining Barclays, Jonathan worked for three years at Citi where he covered the Biotechnology and Specialty Pharmaceuticals sectors. Previously he spent five years at Leerink Swann and two years at HSBC working in Biotechnology equity research.
Prior to his career in financial services, Jonathan was in academia conducting cancer research and teaching at the NYU School of Medicine. He earned a BS in Biochemistry from Ohio University, an MS in Toxicology and a PhD in Toxicology and Carcinogenesis from NYU School of Medicine.
Martin G. Baum brings to SELLAS over 25 years’ experience building and leading global biopharmaceutical companies through continued growth and has held senior executive positions in commercialization, market access, sales and operations.
Most recently, Mr. Baum served as founding partner and Managing Director of Komedica, a healthcare consulting firm. Previously, he founded and served as President and Chief Executive Officer of Vestiq Pharmaceuticals, which was sold to a holding of Praelia Pharmaceuticals Inc. in 2013. Prior to this, Mr. Baum was the President and Chief Executive Officer of Turnberry Development and previously was Founder and Chief Executive Officer of TEAMM Pharma, a specialty pain company that he sold to Accentia Biopharma and took public in 2005. Prior to this, he held the position of Senior Vice President, Commercial Operations at DJ Pharmaceuticals, where he helped achieve profitability within two years and sold the Company to Biovail Corporation. He also was a founding member and served as Senior Vice President of Operations and BD at Skye Pharma PLC, an international company focused on generics and novel drug delivery technologies.
He began his career with Merrell Dow Pharmaceuticals and GlaxoSmithKline Pharmaceuticals. Mr. Baum is a founding member of Health Scape Data and sits on the board of Inno BioPharma, an early stage oncology development company spun out of the University of Iowa. Mr. Baum graduated from the University of Toledo, with BS degrees in Human Life Sciences and Business Administration.
Gregory M. Torre, PhD, JD, is a scientist-attorney with 35 years of hands-on international executive leadership experience in the pharmaceutical and biotech industries.
Prior to joining SELLAS, Dr. Torre served as Vice President, Worldwide Regulatory Strategy – Global Established Products at Pfizer, Inc. Prior to this, he was Vice President of Drug Development at Elusys Therapeutics Inc., and served as Pharmaceutical Science and Legal Consultant at Axiom Law/The Torre Group. Previously, Dr. Torre held senior positions at Alvogen, including Vice President, Regulatory Affairs and Quality; Chief Compliance Officer, and Intellectual Property and Regulatory Council. Prior to joining Alvogen, Dr. Torre was the Senior Vice President for Regulatory Affairs, Quality and Technical Operations at NPS Pharmaceuticals, and he also held positions at MannKind. Prior to this, at Biovest, he was instrumental in developing FDA-acceptable surrogate markers and endpoints for an autologous vaccine to treat non-Hodgkin lymphoma. During his career, Dr. Torre also held leadership positions at Bristol-Myers Squibb, Sanofi, Sankyo and Novartis.
Dr. Torre received his J.D. from Brooklyn Law School, and he is a member of the Bar in the State of New Jersey, the District of Columbia and the United States Supreme Court. He received his BS in Pharmacy from St. John’s University, College of Pharmacy and Allied Health Professions and is a registered Pharmacist in the State of New York. He was also awarded an MS in Pharmacology/Toxicology and a PhD in Pharmacology/Toxicology from the same institution.
Laura M. Katz, MPH, is the Director of Clinical Operations & Biostatistics at SELLAS Life Sciences Group. Laura brings extensive experience in clinical development and clinical and statistical consulting in the pharmaceutical and biotechnology industries.
Prior to joining SELLAS, Laura served as Senior Clinical Project Manager/Senior International Manager at Novo Nordisk in the biopharmaceutical group, where held leading roles on global teams with responsibility for international management of clinical trials in Phases II to IV. Laura was also responsible for the oversight of clinical activities across multiple portfolios in pediatric and adult populations, and directed trials out of both the US and European offices. Previously, Laura served as Associate Director of Biostatistics and Clinical Project Management at Accentia Biopharmaceuticals and as a Consultant at Analytica International and Columbia University.
Laura holds a Master of Public Health in Epidemiology and Biostatistics from Columbia University and a Bachelor of Science in Biostatistics from Cornell University. She has published in prominent journals including the American Journal of Hematology; the American Journal of Public Health; the Journal of the American Academy of Child and Adolescent Psychiatry; and the Annals of Allergy, Asthma, and Immunology.
Prior to SELLAS, Mr. Moser served as Director of Legal Affairs and Secretary of BioVest International, Inc. a subsidiary of Accentia Biopharmaceuticals, where he was responsible for the SEC reporting management for two public biotech companies, documentation and closing of multiple rounds of Private Placement financing, in-house legal oversight of all agreements, S-1 and S-3 drafting, IPO closing, insider trading compliance manager, negotiation, drafting and administration of contracts and more. He also has previously worked in brokerage, civil litigation and general corporate law.
Mr. Moser received a BA degree in Political Science & Economics from Columbia University, New York, and a JD degree from Harvard Law School, Cambridge, MA.